FDA Warning On Ocaliva Puts Intercept's NASH Opportunity In Jeopardy

FDA's warning about 19 deaths related to excessive, off-label dosing for Ocaliva in primary biliary cholangitis spurs fears doctors will curtail prescribing and, worse, that the larger upcoming NASH market opportunity may be affected.